Coloplast A/S Sponsored ADR (OTCMKTS:CLPBY – Get Free Report) saw unusually-high trading volume on Friday . Approximately 1,164,778 shares changed hands during trading, an increase of 161% from the previous session’s volume of 445,557 shares.The stock last traded at $6.62 and had previously closed at $6.6650.
Wall Street Analyst Weigh In
Separately, Sanford C. Bernstein upgraded Coloplast A/S to a “hold” rating in a research report on Wednesday, January 28th. Three analysts have rated the stock with a Hold rating, According to MarketBeat, Coloplast A/S presently has a consensus rating of “Hold”.
View Our Latest Analysis on Coloplast A/S
Coloplast A/S Trading Down 1.1%
Coloplast A/S (OTCMKTS:CLPBY – Get Free Report) last announced its quarterly earnings data on Friday, February 6th. The company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of $0.09 by $0.01. The company had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.12 billion. Coloplast A/S had a return on equity of 27.87% and a net margin of 14.35%. Analysts anticipate that Coloplast A/S Sponsored ADR will post 0.31 earnings per share for the current year.
Coloplast A/S Company Profile
Coloplast A/S is a global developer and manufacturer of medical devices and services focused on intimate healthcare. The company specializes in solutions designed to assist individuals with chronic medical conditions, aiming to improve quality of life through innovative products. Coloplast’s offerings span ostomy care, continence care, wound and skin care, and interventional urology, targeting patients who require long-term support and specialized treatments.
In its ostomy business, Coloplast provides pouches, skin barriers and accessories for patients who have had surgical procedures to divert bodily waste.
Featured Articles
Receive News & Ratings for Coloplast A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coloplast A/S and related companies with MarketBeat.com's FREE daily email newsletter.
